Phase III Study Indicates MF59(R) Adjuvanted Influenza Vaccine, Fluad(R), Is 75 Percent More Efficacious Than Studied Non-Adjuvanted Vaccines In Young Children

CAMBRIDGE, MA--(Marketwire - October 22, 2010) - Novartis Vaccines (NYSE: NVS) •Phase III results demonstrate 89 percent efficacy of Fluad (vs. 45 percent in non-adjuvanted vaccine group) in children between 6 months and 6 years of age against confirmed influenza illness(1)